证券代码：688690 证券简称：纳微科技 公告编号：2025-015 苏州纳微科技股份有限公司 第三届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）第三届董事会第六次会议 于 2025 年 4 月 23 日以现场和通讯相结合方式召开。本次会议由董事长江必旺博 士主持，应出席董事 9 人，实际出席董事 9 人。本次会议的召集和召开程序、出 席人员的资格和议案审议程序均符合《中华人民共和国公司法》等法律法规和 《苏州纳微科技股份有限公司章程》等相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 会议由董事长 BIWANG JACK JIANG（江必旺）召集和主持，审议并一致形成 了以下决议： （一）审议通过《关于公司<2024 年年度报告>及摘要的议案》 经审议，董事会认为公司 2024 年年度报告的编制和审议程序符合法律、法 规、《公司章程》和公司内部管理制度的各项规定；公司 2024 年年度报告的内容 与格式符合中国 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-006 苏州纳微科技股份有限公司 2024 年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 分配比例：A股每10股派发现金红利0.63元（含税），不进行资本公积金 转增股本，不送红股。 本次利润分配以实施权益分派的股权登记日的总股本扣除公司回购专用 证券账户股份数量为基数，具体日期将在权益分派实施公告中明确。 如在本公告披露之日起至实施权益分派的股权登记日前，公司总股本扣 减公司回购专用证券账户中的股份发生变动的，拟维持每股分配的比例不变，相 应调整分配的总额，并将另行公告具体调整情况。 本次利润分配方案不触及《上海证券交易所科创板股票上市规则（2024 年4月修订）》（以下简称《科创板股票上市规则》）第12.9.1条第一款第 （八）项规定的可能被实施其他风险警示的情形。 根据容诚会计师事务所（特殊普通合伙）出具的标准无保留意见审计报告， 公司 2024 年度合并报表中归属于公司股东的净利润为 82,843,363.49 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 第三届董事会第六次会议和第三届监事会第四次会议，审议通过了《关于作废处 理 2022 年、2024 年限制性股票激励计划部分限制性股票的议案》，现将有关事 项说明如下： 一、公司限制性股票激励计划已履行的决策程序和信息披露情况 （一）2022 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2022 年 1 月 28 日，公司召开第二届董事会第六次会议，会议审议通过 了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请股 东大会授权董事会办理股权激励相关事宜的议案》等议案。公司独立董事就本激 励计划相关事项发表了独立意见。 同日，公司召开第二届监事会第五次会议，审议通过了《关于公司<2022 年 限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票 激励计划实 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-013 苏州纳微科技股份有限公司 关于提请股东大会授权董事会以简易程序向特定对象 发行股票并办理相关事宜的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于2025年4月23日召开第 三届董事会第六次会议审议通过了《关于提请股东大会授权董事会以简易程序向 特定对象发行股票并办理相关事宜的议案》，本议案尚需提交公司2024年年度股 东大会审议。 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》等相关规定，为满足公司未来发展需要，公司董事会提请股东 大会授权董事会决定公司择机向特定对象发行融资总额不超过人民币3亿元且不 超过最近一年末净资产20%的股票，授权期限自公司2024年年度股东大会审议通 过之日起至公司2025年年度股东大会召开之日止。本次以简易程序向特定对象发 行股票（以下简称"本次发行"）授权事宜包括但不限于以下内容： 一、本次发行证券的种类和数量 本次发行股票的种类 ...

Dividend and Share Repurchase - The proposed cash dividend for 2024 is CNY 0.63 per 10 shares, totaling approximately CNY 25.25 million for the distribution [8]. - The total amount for cash dividends and share repurchases in 2024 is CNY 86.24 million, representing 104.10% of the net profit attributable to shareholders [8]. - The company has implemented a share repurchase amounting to CNY 60.99 million during the year [8]. - The total share capital as of April 23, 2025, is 403,814,765 shares, with 3,066,622 shares held in the repurchase account excluded from the dividend distribution [8]. Financial Performance - The company's operating revenue for 2024 reached RMB 78,245.67 million, representing a 33.33% increase compared to RMB 58,686.51 million in 2023 [26]. - The net profit attributable to shareholders for 2024 was RMB 8,284.34 million, a 20.82% increase from RMB 6,856.63 million in 2023 [26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 108.55% to RMB 6,587.37 million in 2024 from RMB 3,158.65 million in 2023 [26]. - The net cash flow from operating activities for 2024 was RMB 13,305.52 million, up 5.99% from RMB 12,553.05 million in 2023 [26]. - The total assets at the end of 2024 were RMB 230,959.70 million, an 8.61% increase from RMB 212,656.83 million at the end of 2023 [26]. - The net assets attributable to shareholders increased by 2.64% to RMB 174,842.59 million at the end of 2024 compared to RMB 170,352.79 million at the end of 2023 [26]. Corporate Governance and Audit - The company has received a standard unqualified audit report from Rongcheng Accounting Firm [7]. - The board of directors and supervisory board members have all attended the board meeting, ensuring the report's accuracy and completeness [7]. - The company does not have any special arrangements for corporate governance [10]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [12]. - The company has not conducted any capital reserve transfers to increase share capital or issued bonus shares for the year [8]. Research and Development - The R&D investment for 2024 was 177 million yuan, up 9.61% from the previous year, accounting for 22.64% of the annual operating revenue [28]. - The company is focusing on the development of new technologies and products in the field of chromatography and separation purification [18]. - The company has developed multiple core technologies in microsphere precision preparation, structural control, surface modification, and large-scale production, which are crucial for various fields including biomedicine and diagnostics [89]. - The company has developed a comprehensive microbead precision preparation technology and is one of the few globally capable of large-scale production of both inorganic and organic high-performance nanomaterials [82]. - The company has achieved large-scale production of monodisperse silica chromatographic fillers with a coefficient of variation (CV) of less than 3% [89]. Market Expansion and Strategy - The company plans to expand its market presence and enhance its product offerings in the biopharmaceutical sector [18]. - The company aims to maintain its growth trajectory and improve operational efficiency in the upcoming fiscal year [18]. - The company is focused on expanding its growth potential by leveraging its foundational technology in microsphere precision preparation [63]. - The company aims to establish an overseas application technology center as part of its strategy to expand into international markets [140]. - The company plans to continue expanding its overseas market presence and integrating its "filler + instrument" marketing teams to enhance customer engagement and service [149]. Product Development and Innovation - The new product NMab Titan has significantly improved capacity performance, enhancing the company's product capabilities in antibody applications [39]. - The company launched new products including 3μm and 1.8μm BioCore Glycan analysis columns, designed for therapeutic protein N-glycan analysis [49]. - The company has introduced a new generation of high-performance nucleic acid affinity products, achieving a 90% increase in binding capacity compared to previous models [104]. - The company has developed high-performance microspheres for optoelectronic display applications, with initial customer integration and small-scale sales achieved [103]. - The company has launched a series of gas chromatographs, including the flagship F80, to meet the demands for intelligent, efficient, and precise performance in scientific analysis [96]. Risks and Challenges - The company faces risks related to the potential failure of new product development and the loss of core technical personnel, which could impact its competitive edge [124]. - The company is facing risks related to the uncertainty of the biopharmaceutical market expansion and potential changes in industry policies [138]. - The rapid growth of the Chinese biopharmaceutical market has intensified competition, with both domestic and international companies increasing their focus on this sector [127]. - The company recognizes the need for a collaborative team approach to succeed in the current competitive environment [197]. Operational Efficiency and Cost Management - The company aims to reduce inventory and accounts receivable as part of its cost reduction and efficiency improvement strategy for 2024 [56]. - The company is committed to improving its credit management policies and inventory management through ERP systems to enhance operational efficiency [133]. - The company plans to optimize production processes to improve the stability of core products and reduce production costs [200]. - The company aims to strengthen cost control and optimize financial operations to ensure stable and sustainable development [200]. Acquisitions and Investments - The company completed the acquisition of Fuli Instruments, enhancing its chromatography technology platform following the acquisition of Saipu Instruments in 2022 [52]. - The company acquired a 44.80% stake in Fuli Instruments, gaining control over the board, which will be included in the consolidated financial statements starting March 2024 [157]. - The company plans to establish a wholly-owned subsidiary, Nantong Nawei New Materials Co., Ltd., with an investment of CNY 100 million to enhance its production capacity and market competitiveness [184]. - The company has invested a total of RMB 30 million in the Suzhou Tianhui Microball Investment Partnership, with an investment amount of RMB 15 million reported by the end of the period [189]. Customer and Supplier Relationships - The company has established solid partnerships with numerous pharmaceutical manufacturers, research institutions, and CRO/CDMO enterprises [68]. - The company’s total revenue from the top five customers was 12,782.44 million RMB, accounting for 16.34% of annual sales, with no sales to related parties [158]. - The top five suppliers accounted for 19.66% of the total annual procurement amount, totaling 36.21 million RMB [164]. - The company has established a robust platform for in vitro diagnostic microsphere materials, focusing on high-performance raw materials for diagnostic reagent manufacturers [92].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 188.59 million, representing a year-on-year increase of 22.39%[4] - Net profit attributable to shareholders reached CNY 29.22 million, a significant increase of 72.98% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was CNY 25.08 million, reflecting an 85.28% year-on-year growth[4] - Basic earnings per share were CNY 0.0729, up 73.99% from the previous year[4] - The total profit for the first quarter of 2025 was CNY 30,561,117.82, compared to CNY 18,872,862.75 in the same period of 2024, representing a year-over-year increase of 62.5%[18] - The net profit attributable to shareholders of the parent company for Q1 2025 was CNY 29,215,389.59, up from CNY 16,889,348.07 in Q1 2024, reflecting a growth of 73.1%[18] - The basic and diluted earnings per share for Q1 2025 were CNY 0.0729, an increase from CNY 0.0419 in Q1 2024, representing a growth of 74.5%[18] Research and Development - The company's R&D investment totaled CNY 45.69 million, accounting for 24.23% of operating revenue, a decrease of 2.88 percentage points year-on-year[5] - Research and development expenses for Q1 2025 were ¥45,688,886.66, compared to ¥41,775,828.89 in Q1 2024, an increase of 9.1%[17] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 5.30 million, a decline of 157.78% compared to the previous year[4] - The operating cash flow for Q1 2025 was negative at CNY -5,302,608.25, a decline from a positive cash flow of CNY 9,177,879.67 in Q1 2024[20] - Cash inflows from operating activities totaled CNY 208,567,680.88 in Q1 2025, compared to CNY 143,694,631.67 in Q1 2024, marking an increase of 45.2%[20] - Cash outflows from operating activities increased to CNY 213,870,289.13 in Q1 2025, up from CNY 134,516,752.00 in Q1 2024, indicating a rise of 58.8%[20] - The net cash flow from investing activities for Q1 2025 was CNY 22,652,504.36, a significant improvement from a negative cash flow of CNY -14,680,684.84 in Q1 2024[21] - The total cash and cash equivalents at the end of Q1 2025 stood at CNY 277,175,586.10, compared to CNY 293,987,971.63 at the end of Q1 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,285.47 million, down 1.04% from the end of the previous year[5] - Total assets as of March 31, 2025, were ¥2,285,471,743.28, down from ¥2,309,596,977.25 at the end of 2024[14] - Total liabilities decreased to ¥353,442,368.20 from ¥421,525,181.46, a reduction of 16.1%[15] - Shareholders' equity increased to ¥1,932,029,375.08 from ¥1,888,071,795.79, reflecting a growth of 2.3%[15] Operational Efficiency - The core business of chromatography fillers and media generated approximately CNY 111 million in revenue, a growth of about 10.62% year-on-year[6] - The company is focusing on enhancing quality and efficiency, which has positively impacted revenue and cost management[7] - Total operating costs for Q1 2025 were ¥161,106,017.03, up 24.3% from ¥129,526,550.05 in Q1 2024[17] - Operating profit for Q1 2025 was ¥30,598,775.21, compared to ¥19,332,551.34 in Q1 2024, reflecting a growth of 58.1%[17] Other Comprehensive Income - The company reported a decrease in other comprehensive income, with a net amount of CNY -33,250.09 in Q1 2025, compared to CNY 32,787.55 in Q1 2024[18]

非经营性资金占用及其他关联资金 往来情况专项说明 苏州纳微科技股份有限公司 容诚专字[2025]200Z0334号 容诚会计师事务所(特殊普通合伙 ) 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金 往来、对外担保的监管要求》的要求及上海证券交易所《科创板上市公司自律监 管指南第 7 号——年度报告相关事项》的规定，纳微科技公司管理层编制了后附 的苏州纳微科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情 况汇总表（以下简称汇总表）。如实编制和对外披露汇总表并保证其真实、准确、 完整是纳微科技公司管理层的责任。 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 关于苏州纳微科技股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 容诚专字[2025]200Z0334号 苏州 ...

二〇二五年四月 北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2022 年限制性股票激励计划 部分限制性股票作废事项的 法律意见书 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2022 年限制性股票激励计划 部分限制性股票作废事项的 法律意见书 致苏州纳微科技股份有限公司： 北京市中伦（上海）律师事务所（以下简称"本所"）接受苏州纳微科技股 份有限公司（以下简称"纳微科技"或"公司"）的委托，就公司 2022 年 ...

内部控制审计报告 苏州纳微科技股份有限公司 容诚审字[2025]200Z2021号 容诚会计师事务所(特殊普通合伙 ) 中国·北京 二、注册会计师的责任 内部控制审计报告 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚审字[2025]200Z2021号 苏州纳微科技股份有限公司 全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们 审计了苏州纳微科技股份有限公司（以下简称"纳微科技公司"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控 制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是纳微科技 公司董事会的责任。 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发 ...

北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2024 年限制性股票激励计划 部分限制性股票作废事项的 法律意见书 二〇二五年四月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2024 年限制性股票激励计划 部分限制性股票作废事项的 法律意见书 致苏州纳微科技股份有限公司： 北京市中伦（上海）律师事务所（以下简称"本所"）接受苏州纳微科技股 份有限公司（以下简称"纳微科技"或"公司"）的委托，就公司 2024 年 ...